Disease and the immune response
Pathogenesis—literally how disease (pathos) begins (genesis) or develops—is a broad and important area of research.
Many diseases can arise from pathogens, but the immune system protects us through various lines of defense. If the immune system fails to function properly and becomes too weak or too strong, it can lead to disease states that include immunodeficiencies that lead to enhanced susceptibly to infections disease, autoimmune conditions, such as lupus and arthritis, and even cancer.
Director's statement
Our focus is on understanding the regulation and interplay of host immune responses and microbial pathogenesis. We study pathogen-host interactions, innate and humoral immunity, inflammation and T cell checkpoint regulation. A better understanding of these aspects of the immune system will provide novel therapeutic opportunities to address many unmet medical needs, including the treatment of endemic and pandemic infectious diseases, autoimmune disorders, cancer and inflammatory diseases.
– Jamey Marth, Ph.D., Program Director
Appointments
Program Director
Primary Appointments
Victoria Blaho, Ph.D.
Sumit Chanda, Ph.D.
Andrei Osterman, Ph.D.
Carl F. Ware, Ph.D.
Secondary Appointments
Linda Bradley, Ph.D.
Maximiliano D'Angelo, Ph.D.
Ze'ev Ronai, Ph.D.
Guy Salvesen, Ph.D.
Evan Snyder, M.D., Ph.D.
Publications
Realigning the LIGHT signaling network to control dysregulated inflammation.
Ware CF, Croft M, Neil GA
J Exp Med 2022 Jul 4 ;219(7)
Shared and Unique Evolutionary Trajectories to Ciprofloxacin Resistance in Gram-Negative Bacterial Pathogens.
Zlamal JE, Leyn SA, Iyer M, Elane ML, Wong NA, Wamsley JW, Vercruysse M, Garcia-Alcalde F, Osterman AL
mBio 2021 Jun 29 ;12(3):e0098721
Sphingosine 1-phosphate escapes the Catch-22 of sepsis prevention and mitigation therapies.
Blaho VA
EBioMedicine 2020 Sep ;59:102952
Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity.
Pohl MO, Martin-Sancho L, Ratnayake R, White KM, Riva L, Chen QY, Lieber G, Busnadiego I, Yin X, Lin S, Pu Y, Pache L, Rosales R, Déjosez M, Qin Y, De Jesus PD, Beall A, Yoh S, Hale BG, Zwaka TP, Matsunaga N, García-Sastre A, Stertz S, Chanda SK, Luesch H
ACS Infect Dis 2022 Jul 8 ;8(7):1265-1279
Synthetic lethality-based prediction of anti-SARS-CoV-2 targets.
Pal LR, Cheng K, Nair NU, Martin-Sancho L, Sinha S, Pu Y, Riva L, Yin X, Schischlik F, Lee JS, Chanda SK, Ruppin E
iScience 2022 May 20 ;25(5):104311
Btla signaling in conventional and regulatory lymphocytes coordinately tempers humoral immunity in the intestinal mucosa.
Stienne C, Virgen-Slane R, Elmén L, Veny M, Huang S, Nguyen J, Chappell E, Balmert MO, Shui JW, Hurchla MA, Kronenberg M, Peterson SN, Murphy KM, Ware CF, Šedý JR
Cell Rep 2022 Mar 22 ;38(12):110553
NFAM1 Promotes Pro-Inflammatory Cytokine Production in Mouse and Human Monocytes.
Juchem KW, Gounder AP, Gao JP, Seccareccia E, Yeddula N, Huffmaster NJ, Côté-Martin A, Fogal SE, Souza D, Wang SS, Glynn ERA, Yung I, Ritchie J, Li L, Zheng J, Mbow ML, Li J, Chanda SK
Front Immunol 2021 ;12:773445
Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques.
Madden PJ, Arif MS, Becker ME, McRaven MD, Carias AM, Lorenzo-Redondo R, Xiao S, Midkiff CC, Blair RV, Potter EL, Martin-Sancho L, Dodson A, Martinelli E, Todd JM, Villinger FJ, Chanda SK, Aye PP, Roy CJ, Roederer M, Lewis MG, Veazey RS, Hope TJ
Front Immunol 2021 ;12:810047
Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
Cheng K, Martin-Sancho L, Pal LR, Pu Y, Riva L, Yin X, Sinha S, Nair NU, Chanda SK, Ruppin E
Mol Syst Biol 2021 Nov ;17(11):e10260